Title

Update from the 2013 international neurofibromatosis conference

Authors

Scott R. Plotkin, Massachusetts General Hospital
Anne C. Albers, Washington University School of Medicine in St. Louis
Dusica Babovic-Vuksanovic, Mayo Clinic
Jaishri O. Blakeley, Johns Hopkins University
Xandra O. Breakefield, Massachusetts General Hospital
Courtney M. Dunn, Washington University School of Medicine in St. Louis
D. Gareth Evans, The University of Manchester
Michael J. Fisher, The Children's Hospital of Philadelphia
Jan M. Friedman, The University of British Columbia
Marco Giovannini, House Research Institute
David H. Gutmann, Washington University School of Medicine in St. Louis
Michel Kalamarides, Hôpital Universitaire Pitié Salpêtrière
Andrea I. Mcclatchey, Massachusetts General Hospital
Ludwine Messiaen, The University of Alabama at Birmingham
Helen Morrison, Leibniz Institute on Aging - Fritz Lipmann Institute
David B. Parkinson, Plymouth University, Peninsula Schools of Medicine and Dentistry
Anat O. Stemmer-Rachamimov, Massachusetts General Hospital
Catherine D. Van Raamsdonk, The University of British Columbia
Vincent M. Riccardi, Neurofibromatosis Institute
Tena Rosser, University of Southern California
Aaron Schindeler, The University of Sydney
Miriam J. Smith, The University of Manchester
David A. Stevenson, The University of Utah
Nicole J. Ullrich, Children's Hospital Boston
Thijs van der Vaart, Erasmus MC
Brian Weiss, Cincinnati Children's Hospital Medical Center
Brigitte C. Widemann, National Cancer Institute (NCI)
Yuan Zhu, Childrens National Health System
Annette C. Bakker, Children's Tumor Foundation
Alison C. Lloyd, University College London

Document Type

Journal Article

Publication Date

12-1-2014

Journal

American Journal of Medical Genetics, Part A

Volume

164

Issue

12

DOI

10.1002/ajmg.a.36754

Keywords

Merlin; Neurofibromatosis 1; Neurofibromatosis 2; Neurofibromin; NF1; NF2; Preclinical models; Schwannomatosis; SMARCB1; Tumor suppressor

Share

COinS